Minimally invasive treatments like prostatic artery embolization (PAE) are effective, low-morbidity alternatives for managing large-volume benign prostatic hyperplasia. This case report describes a ...

Erectile Dysfunction - Read the latest Erectile Dysfunction research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

Looking for the latest abstracts on prostate cancer treatment and research? We've got you covered and then some.

Peter Clark presented results from the SunRISe-1 study at SESAUA 2025, evaluating TAR-200, an intravesical sustained-release gemcitabine system, in BCG-unresponsive high-risk non-muscle invasive ...

For decades, platinum-based chemotherapy was the mainstay of first-line treatment, offering modest efficacy. Anticipated median survival was limited at around 15 months. 1 Additionally, many patients ...

Peyronie's Disease - Read the latest Peyronie's Disease research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

ASCO 2025, Non–muscle-Invasive Bladder Cancer (NMIBC), Intravesical Sacituzumab Tirumotecan, Intermediate-Risk Non–muscle-Invasive Bladder Cancer, TroFuse-027 Study, Trophoblast cell-surface antigen 2 ...

Bladder Research - Read the latest Bladder Research research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

Bladder Cancer - Read the latest Bladder Cancer research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

As part of an independent medical education initiative, Beyond Androgen Blockade to New Pathways and Novel Treatments in Metastatic Hormone-Sensitive Prostate Cancer and Metastatic ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment.